We are a clinical-stage biopharmaceutical company
advancing a portfolio of novel fatty acid synthase (FASN) inhibitors. FASN is a key regulator of the de novo lipogenesis pathway, which is overactive in acne and can cause elevated sebum and inflammation. FASN is also implicated in other diseases, including MASH and certain FASN-dependent tumor types.
Denifanstat
Our lead product candidate, denifanstat, is an oral, once-daily FASN inhibitor with a differentiated method of action with the potential to target multiple underserved diseases. Denifanstat is currently being evaluated in a U.S. Phase 3 registrational clinical trial for moderate to severe acne.
Development Pipeline: Indications and Clinical Milestones
Stage of Development
Therapeutic area
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Dermatology
Denifanstat - First patient dosed in AURORA Phase 3 clinical trial in Oct 2026
TVB-3567
FASNi Topical*
Denifanstat (ASC40)
Metabolic
disease
Denifanstat Phase 3 ready (F2/F3MASH)
Denifanstat Ph1 hepatic impairment study complete
Denifanstat/resmetirom Ph 1 PK trial complete
*FASN inhibitor Topical Formulation
